Kornimate/medical-research-clean huggingface dataset:
a nation-wide hospital-based hepatitis b registry:china registry of hepatitis b

Conditions: Chronic Hepatitis B

Summary: cr-hepb registry started in june 30,2012 to collect hbv cases from general hospitals or specialized hospitals for infectious diseases in mainland china. demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. the main criteria for registration is hbsag-positivity more than 6 months, and these patients will receive followed-up visits every three to six months.

this web-based database was launched on june 30, 2012 and consists of tertiary or secondary hospitals with special interest and expertise on managing hepatitis b patients across mainland china. the main inclusion criteria for this registration are hbsag-positivity ≥ 6 months, hbeag positive or negative, with or without cirrhosis, either treatment-naïve or treatment experienced. at the first time of data entry, demographics, medical history, virology, biochemistry and hematology results, radiology reports, diagnosis and treatment information were recorded. then the registered patients received standard of care and follow-up every 3 to 6 months. on each visit, virological, biochemical, and radiological reports, as well as clinical progress were recorded.

Eligibility criteria:
inclusion criteria: * hbsag-positivity over a continuous six months. the core exclusion criteria are: 1) hcc patients for their treatment mainly depends on surgical operation and interventional therapy, but not the antiviral therapy; 2) patients who are unable or unwilling to provide informed consent.

Keywords: hepatitis b，registry,cirrhosis, hcc
a phase ii prospective, single blinded, randomized trial of hemopatch compared to standard techniques to achieve air leak control after complex thoracic surgical procedures

Conditions: Thoracic Surgery Lung; Post-operative Thoracic Air Leak

Summary: the purpose of this study is to explore whether the addition of hemopatch to standard care can reduce prolonged air leaks and shorten the use of air drainage tube after surgery in thoracic lung surgery patients at high risk for prolonged air leaks.


Eligibility criteria:
inclusion criteria: * age ≥18 years * high risk of prolonged air leak due to at least one of the following reasons: * preoperative fev1\<80% * dlco \< 80% * lvrs (lung volume reduction surgery o pneumoplastica riduttiva) * anticipation of intraoperative adhesions (ie, redo surgery) * previous induction chemotherapy for locally advanced nsclc * chronic steroid use * pleural mesothelioma * candidate to one of the following major thoracic surgical intervention: * decortication * reintervention on the same side of the previous intervention * segmentectomy * lobectomy with incomplete fissures on ct scan * written informed consent. exclusion criteria: * pregnancy or breast-feeding * evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the informed consent form or their ability to comply with study requirements * any unstable systemic disease (including active infections, any significant hepatic, renal or cardiovascular disease), metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates or prevents or the execution of surgery * known hypersensitivity to bovine proteins or brilliant blue (fd\&c blue no.1)

Keywords: pulmonary resection chest tube segmentectomy lobectomy
tissue perfusion for different approaches of brachial plexus block

Conditions: Upper Extremity Fracture; Regional Anesthesia; Brachial Plexus Blocks; Perfusion Index; Tissue Perfusion

Summary: to compare the two different approaches of infraclavicular brachial plexus block in forearm, wrist and hand surgery in terms of perfusion index, tissue oxygenation, sensory and motor block onset time and total effect time, first analgesic time, side effects and complications, and duration of block application.


Eligibility criteria:
inclusion criteria: * patients who undergo elective forearm or hand surgery under infraclavicular brachial plexus block * american society of anesthesiologists class 1 to 3 * ability to consent exclusion criteria: * history of allergic reaction to local anaesthetics * peripheral neuropathy * renal or hepatic insufficiency * coagulation disorders

Keywords: lateral sagittal approach costoclavicular approach block success perfusion index brachial plexus
the purpose of the study is to continue to provide pemigatinib to patients with advanced malignancies.

Conditions: Advanced Malignancies

Summary: safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.

a phase 2 open-label, multicenter, rollover study to evaluate the long term safety and tolerability of pemigatinib and to provide continued treatment for participants with advanced malignancies previously enrolled in studies of pemigatinib

Eligibility criteria:
inclusion criteria: * currently enrolled and receiving treatment in an incyte-sponsored clinical study (parent protocol) of pemigatinib as monotherapy or combination therapy. * currently benefiting from and tolerating treatment with pemigatinib, as determined by the investigator. * demonstrated compliance, as assessed by the investigator, with the parent protocol requirements. * willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures. * currently have no evidence of progressive disease, as determined by the investigator, following treatment with pemigatinib as monotherapy or combination therapy. * willingness to avoid pregnancy or fathering children. exclusion criteria: * able to access pemigatinib commercially or outside of a clinical trial. * permanently discontinued from the parent protocol for any reason. * no longer meet the inclusion/exclusion criteria from the parent protocol if still receiving treatment. * women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study.

Keywords: pemigatinib
mammaprint value for pre-menopausal breast cancer patients

Conditions: Breast Cancer

Summary: nearly 200 cases are to be enrolled. the information of patient age, histologic grade, tumor size, er and pr status, ki-67 index, surgery mode should be provided. the adjuvant therapy regime (chemotherapy: none, tc\*4, tc\*6 or ec-t; endocrine therapy: tam, ofs+tam, ofs+ai) will be compared before and after mammaprint testing. about 20 clinical staffs are enrolled to participate in this survey for the clinical decision making. each case could be chosen five times at random.


Eligibility criteria:
inclusion criteria: 1. pre-menopausal breast cancer patients aged less than 50 years old. 2. pathology confirmed invasive dutal carcinoma or invasive lobular carcinoma. 3. receiving breast conserving surgery or mastectomy with/without reconstruction; sentinel lymph node biopsy or axillary lymph node dissection. 4. tnm staging: t1b-t2n0-1m0. 5. molecular subtype: er positive/her2 negative. 6. mammaprint testing before initiation of adjuvant therapy. exclusion criteria: 1. incomplete medical history. 2. pregnancy or lactation. 3. contradiction of chemotherapy or ovarian function suppression.
clinical outcomes of transvaginal mesh procedures for cystocele repair: comparisons of uphold and perigee systems

Conditions: Pelvic Organ Prolapse; Surgical Mesh

Summary: pelvic organ prolapse (pop) is a major health concern, affecting more than 30% of women. the aim of this study was to compare the clinical outcomes of uphold system and perigee system in treating women with cystocele.

pelvic organ prolapse (pop) is a major health concern, affecting more than 30% of women. traditional vaginal surgery with native tissue is associated with high recurrence rate. thus, synthetic meshes were introduced into pop surgery and became the mainstream. several transvaginal mesh procedures, such as uphold system (boston scientific) and perigee system (american medical systems inc), have been used for cystocele repair. perigee system is a trans-obturator four-arm mesh device attached to proximal and distal arcus tendineus fasciae pelvis. nonetheless, uphold system, is a single incised, two-arm anterior sacrospinous mesh fixation system. both systems can be used for cystocele repair, despite uphold system can be used for concomitant repair of apical prolapse. the aim of this study was to compare the clinical outcomes of uphold system and perigee system in treating women with cystocele.

Eligibility criteria:
inclusion criteria: 1. vaginal anterior wall prolapse greater than or equal to second phase of pop-q 2. underwent uphold or perigee procedures exclusion criteria: * nil
application of artificial intelligence on the diagnosis of helicobacter pylori infection and premalignant gastric lesion

Conditions: Helicobacter Pylori Infection; Premalignant Lesion

Summary: the aim of this diagnostic accuracy study is to evaluate the application of artificial intelligence on the diagnosis of helicobacter pylori infection and premalignant gastric lesions based on upper endoscopic images. we use techniques of artificial intelligence to analyze the correlation between endoscopic images and urea breath test results/histopathological results.

this study had invited patients to undergo urea breath test, upper gastrointestinal endoscopy, and histology examination. the study will collect their tests results, upper gastrointestinal endoscopy images, and histopathological results. artificial intelligence techniques will be used to analyze the correlation between endoscopic images and urea breath test results/histopathological results. we aim to establish a telemedicine system to assist clinicians in diagnosing helicobacter pylori infection and detecting premalignant gastric lesion using upper endoscopic images. the system will be implemented as a telemedicine service system in the rural areas, for example matsu islands. the baseline histological predictions will be linked to the newly incident gastric cancer.

Eligibility criteria:
inclusion criteria: 1. age 20-80 2. scheduled urea breath test and endoscopy exclusion criteria: 1. history of gastric surgery

Keywords: helicobacter, artificial intelligence, telemedicine
high-fidelity simulation training: a mixed method study

Conditions: Simulation of Physical Illness; Satisfaction

Summary: the goal of this clinical trial is to compare in describe first-year nursing students' skills. the main questions it aims to answer are: * are nursing students who perform the simulation practice with the scenario-based high-fidelity simulation manikin higher than those who perform the practice with the standard demonstration method? * are the satisfaction levels of nursing students who perform the simulation practice with the scenario-based high-fidelity simulation manikin higher than those who perform the practice with the standard demonstration method? researchers will compare two groups of nursing students training with high-fidelity simulation manikin and training with standard demonstration method.


Eligibility criteria:
inclusion criteria: * first-year nursing students * not have been trained in simulation before * taking a nursing fundamentals course for the first time * open to communication and volunteering to be involved in the study exclusion criteria: * not meeting the inclusion criteria * not volunteering to participate in the study

Keywords: covid-19 simulation personal protective equipment nurse
therapy of bronchoalveolar lavage and local amikacin injection in patients with acute exacerbation of bronchiectasis

Conditions: Bronchiectasis

Summary: the therapy of bronchoalveolar lavage and local amikacin injection as one of the treatment of bronchiectasis developed in recent years.this study is aim to evaluate the clinical efficacy and safety of therapy of bronchoalveolar lavage and local amikacin injection in patients with acute exacerbation of bronchiectasis.

the aim of this study was to evaluate the efficacy and safety of the therapy of bronchoalveolar lavage and local amikacin injection through the observation of a large sample of clinical cases. during the observation, study visits will occur at the end of 30days, 60days, 90days.all the participants will be required to check the various efficacy and safety indicators.

Eligibility criteria:
inclusion criteria: 1. age≥18 years and ≤80 years; 2. patients with non-cystic fibrosis bronchiectasis diagnosed by high-resolution ct; 3. are sensitive to amikacin; 4. acute exacerbation of bronchiectasis; 5. capable of the completion of bronchoscopy, alveolar lavage, pulmonary function testing etc; 6. willing to join in and sign the informed consent form. exclusion criteria: 1. active bleeding without control； 2. receiving nasal or facial surgery recently； 3. with severe cardio-pulmonary dysfunction, such as left heart failure, unstable arrhythmia, etc. 4. with other respiratory diseases: such as active pulmonary tuberculosis, non-tuberculosis mycobacteria (ntm) pulmonary disease, pulmonary aspergillosis, etc. 5. be allergic to amikacin
change of glucose metabolism and fibrosis markers in patients with hepatitis c under treatment with antiviral agents

Conditions: Glucose Metabolism Disorders; Liver Fibrosis; Hepatitis C

Summary: chronic hepatitis c infection is associated with changes of glucose metabolism end increased frequency of impaired glucose tolerance. this might be a additional risk factor for disease and fibrosis progression. the study aims to evaluate whether a therapy with direct-acting antiviral agents leading to a sustained virologic response directly impacts parameters reflecting glucose metabolism and fibrosis.

chronic hepatitis c infection is associated with changes of glucose metabolism end increased frequency of impaired glucose tolerance. it is well known that metabolic factors play an important role in fibrosis progression and steatohepatitis for example in non-alcoholic steatohepatitis (nash). accordingly changes in glucose metabolism in patients with chronic hepatitis c might directly impact disease and fibrosis progression. the study aims to evaluate whether a therapy with direct-acting antiviral agents leading to a sustained virologic response directly impacts parameters reflecting glucose metabolism and fibrosis. follow-up examinations will determine the long-term metabolic changes of successful elimination of the virus by antiviral treatment.

Eligibility criteria:
inclusion criteria: 1. patients with chronic hepatitis c infection and planned antiviral therapy with direct-acting antiviral agents 2. age 18-99 3. informed consent exclusion criteria: 1. patients without legal capacity for informed consent 2. alcohol intake ≥ 20 g/d (f) und 30 g/d (m) within one year of study screening 3. decompensated cirrhosis 4. viral co-infection 5. hiv infection 6. non-viral chronic liver disease 7. malignancy within 5 years before study screening except basalioma 8. liver transplant recipients 9. weight loss ≥10% within 3 months before study screening 10. changes of diabetic drug treatment, lipid lowering therapy oder vitamin e within three months before study screening. 11. intake of medication associated with hepatic steatosis (e.g. steroids, methotrexate, amiodarone, tamoxifen, valproat, flutamide, tetracyclins, cytostatics etc.) 12. bariatric surgery in personal history 13. clinically relevant congestive heart disease, cardiac arrythmia, valvular heart disease) 14. implanted cardiac pacemaker or defibrillator 15. patients during pregnancy or lactation
prospective intraperitoneal chemotherapy in carcinomatosis cohort study

Conditions: Peritoneal Carcinomatosis

Summary: evaluation of clinical outcome and economical aspects in the treatment of patients with peritoneal carcinomatosis.

peritoneal carcinomatosis is a dooming finding with no hope for cure and a steadily decrease in quality of life. cytoreductive surgery with intraperitoneal chemotherapy (crs hipec) offers a small but proven chance for cure. the implementation of a crs hipec and pipac programme in a swiss tertiary care hospital is evaluated. when a patient is deemed non resectable, pressurized intraperitoneal aerosol chemotherapy (pipac) administered laparoscopically may confer effective palliation.

Eligibility criteria:
inclusion criteria: * men and women \>18 years * tumour board decision for crs and intraoperative chemotherapy exclusion criteria: * missing tumour board decision for crs and intraoperative chemotherapy * pregnancy * age \<18 years
efeso - efficacy enterogermina small intestinal bacterial overgrowth

Conditions: Irritable Bowel Syndrome

Summary: primary objective: to assess the efficacy of bacillus clausii versus metronidazole in the eradication of the small intestinal bacterial overgrowth, 30 days after the end of treatment. secondary objective: to assess the efficacy of bacillus clausii versus metronidazole in avoiding recurrence of the small intestinal bacterial overgrowth, 90 days after the end of the treatment; to assess the efficacy of bacillus clausiiversus metronidazole in improving irritable bowel syndrome -related symptoms; to assess the efficacy of bacillus clausii versus metronidazole in the satisfactory relief of overall irritable bowel syndrome symptoms and of abdominal discomfort or pain; to assess the efficacy of bacillus clausii versus metronidazole in improving irritable bowel syndrome quality of life.


Eligibility criteria:
inclusion criteria: * irritable bowel syndrome patients with small intestinal bacterial overgrowth (based on positive lactulose or glucose hydrogen breath test) * patients able to maintain their usual diet and lifestyle during the course of the study. exclusion criteria: * pregnancy or breast-feeding * major concomitant diseases (including tumours and hepatic and/or renal insufficiency) * inflammatory bowel diseases * history of intestinal surgery (except cholecystectomy and appendectomy) * use of antibiotic, laxative, antidiarrheic drugs or probiotics (medications or dietetic supplements) in the last month prior to study entry * hypersensibility to the investigational product and reference drug * clinical evidence of relevant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurologic or of any disease that may interfere with the patient successfully completing the trial or the objectives of the trial * eating disorders such as anorexia or bulimia, and/or psychosis, schizophrenia, mania or major psychiatric illness needing pharmacological treatment. well-compensated depression does not exclude a potential patient * participation to a trial in the previous three months * drug or alcohol abuse * subjects with unstable personality or not able to be compliant with the study procedures the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
modified pectoral nerves block versus serratus plane block in major breast cancer surgery

Conditions: Postoperative Pain

Summary: the purpose of this study is to compare the analgesic profile of modified pectoral nerves block and serratus plane block in patients undergoing mastectomy.

this study includes three groups. the first group will receive ultrasound-guided modified pectoral nerves block prior to induction of general anesthesia. the second one will receive ultrasound-guided serratus plane block prior to induction of general anesthesia. the third one will not receive any block preoperatively.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists( asa) i or ii and scheduled for major breast cancer surgery( modified radical mastectomy or conservative mastectomy with axillary evacuation). exclusion criteria: * local infection at the site of the block, coagulations abnormalities, allergy to local anesthetics or morphine, body mass index\> 35, patient refusal, severe respiratory or cardiac disorders, pre-existing neurological deficits, hepatic or renal insufficiency, chronic pain syndrome, chronic analgesic use and psychiatric disorders.
tolerability of transcranial direct current stimulation in pediatric stroke survivors

Conditions: Childhood Stroke

Summary: the purpose of this study is to evaluate the tolerability of tdcs in childhood stroke survivors and to assess for improvement in arm function in patients receiving tdcs and occupational therapy


Eligibility criteria:
inclusion criteria: * childhood stroke survivor - either arterial ischemic stroke or intracerebral hemorrhage. * stroke must be childhood onset, defined as occurring day 29 of life to 18 years of age (per the american heart association's definition of childhood stroke) * 3 months or greater from stroke onset * arm impairment, defined as pediatric stroke outcome measure of 1 or greater of affected arm. * affected arm fugl-meyer score of 60 or lower. * able to participate in occupational therapy sessions. exclusion criteria: * uncontrolled epilepsy, defined as seizure within the past 6 months. * craniectomy without replacement of bone flap. patients who underwent craniectomy will need the bone flap reattached prior to participation. * presence of cranial metal implants or implant device that could be affected by tdcs: cochlear implant, implanted brain stimulator, or programmable ventriculoperitoneal shunt.

Keywords: neuromodulation transcranial direct current stimulation stroke rehabilitation childhood stroke
nutritional follow up after hospital discharge for coronavirus disease-19

Conditions: Covid-19

Summary: coronavirus infection is responsible for muscle wasting (sarcopenia), especially during prolonged stays in intensive care. sarcopenia, in its functional aspect also seems major in patients hospitalized for this infection, in non-icu unit. weight loss also appears to be significant, despite a prevalence of overweight and obesity in severe forms. undernutrition in the obese patient is also possible (undernourished obese and sarcopenia obesity). anosmia and dysgeusia participate in undernutrition by reducing energy intake. the rehabilitation of these patients requires nutritional support (increased protein intake) associated with progressive retraining to physical activity. an early and proactive management procedure within coronavirus disease-19 units has been implemented in conjunction with the transversal nutrition unit (tnu). this nutritional care must be continued after discharge. follow-up by teleconsultation or telephone consultation is put in place after the patient's discharge primary objective: evaluation of nutritional status at the time of admission and discharge and home follow-up in outgoing patients from coronavirus disease-19 units secondary objectives: description of the evolution of food intake, diversity of food and coverage of needs evaluation of the muscular strength of the wrist (by grip test in hospital) and on the arms and legs after return home (visual analog scale) evolution of anosmia and dysgeusia (at the time of hospital admission, at the time of hospital discharge and at home) level of physical training before infection (ipaq) description of the general state of health measured by the performance index - world health organization scale description of nutritional prescriptions description of the prevention measures and incidence of inappropriate refeeding syndrome (irs) care needs assessments


Eligibility criteria:
inclusion criteria: * covid positive (rt-pcr) exclusion criteria: * unable to answer questions by telephone or teleconsultation directly or through a relative, minors under 16 years of age

Keywords: nutritional status malnutrition diet intervention sarcopenia muscle strength